INTRODUCTORY STATEMENT  

Local anesthetic agents are among the most widely used drugs.  The use of regional, epidural and intrathecal local anesthesia for surgical procedures has increased continuously during the past decade due to the introduction of new minimally invasive surgical techniques that can be ambulatory performed. Local anesthetics are also applied by physicians to relieve unpleasant sensations and reactions to other procedures such as tracheal intubation, venipunction, etc.  

In all those applications the final effect of local anesthetics is an inhibition of electrical activity, accomplished as a reduction or total blockade of action potentials. The primary site of action is the sodium channel, a transmembrane protein which is essential for the influx of sodium ions that subserves impulse generation and propagation in nerves, skeletal muscle and heart.  

Despite of the wide use of this type of compounds and the large amount of synthesized derivatives, only a few are currently used. Most of them belong to the family of lidocaine (amides) although some esters are also used. Their clinical efficacy and safety are rather satisfactory although sometimes some cardiac side effects and toxicity on CNS are seen. Sometimes, the duration of the anesthetic effects must be enhanced and this is accomplished by adding epinephrine to constrict capillaries in the site of the injection and to maintain high local concentrations of the drug. In general, local anesthetics are rapidly metabolized and cleared from the site of the injection.  
 

Chemical structure of IQB-9302 In order to improve the tissue distribution and fixation of the anaesthetic molecule, scientists at IQB designed a series of amide anaesthetic derivatives bearing a 
cyclopropyl group linked to the side chain.  

This low molecular alkyl group maintains steric and lipophylic properties of the most potent amide anesthetics, such as bupivacaine, but seems to be less sensitive to enzymatic metabolization thus maintaining a higher duration of action

From this series, IQB-9302 (tentative INN = ciprocaine) was selected because of its long duration of action and relatively low toxicity shown in the preliminary screening 
 
 

PROJECT HOMEPAGE